BCAL Diagnostics (ASX:BDX) Total Receivables: A$0.11 Mil (As of Dec. 2025)


What is BCAL Diagnostics Total Receivables?

BCAL Diagnostics ASX:BDX +4.17% Total Receivables is A$0.11 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's Total Receivables for the quarter that ended in Dec. 2025 was A$0.11 Mil.

BCAL Diagnostics Total Receivables Related Terms

BCAL Diagnostics Total Receivables Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Total Receivables Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Receivables
0.01 0.00 0.04 0.01

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.04 1.34 0.01 0.11

BCAL Diagnostics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$0.11 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Total Receivables of A$0.11 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Total Receivables too high?
BCAL Diagnostics' current Total Receivables is A$0.11 Mil.
How does BCAL Diagnostics' Total Receivables compare to TMO and DHR?
BCAL Diagnostics' Total Receivables of A$0.11 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Total Receivables is A$0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Total Receivables of A$0.11 Mil. The current Total Receivables is A$0.11 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Total Receivables is A$0.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.